Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes
Ciuca, I.; Bulandra, R.; Serbanesco, L.; Ninosu, N.
Revue Neurologique (Paris) 127(2): 305-308
1972
ISSN/ISBN: 0035-3787 PMID: 4672049 Document Number: 57087
Document emailed within 1 workday
Related Documents
Ambrosetto, C.; Martinelli, P. 1971: Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa Minerva Medica 62(82): 4017-4019Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Puca, F.M.; Bricolo, A.; Turella, G. 1972: Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes Revue Neurologique (Paris) 127(2): 313
Quattrini, A.; Paggi, A.; Forastieri, L.; Del Pesce, M.; Di Bella, P. 1979: Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) Rivista di Patologia Nervosa e Mentale 99(5): 289-297
Rabadeau Dumas, J.L.; Rondot, P.; Cardon, P. 1977: Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor Therapie 32(2): 161-172
Dzudza, M.; Dzudza, D. 1974: Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease Medicinski Arhiv 28(4): 407-415
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Agnoli, A.; Casacchia, M.; Ruggieri, S.; Volante, F.; Accornero, N. 1971: Action of amantadine on parkinsonian tremor Minerva Medica 62(82): 3990-3993
Kadykov, A.S. 1976: The effectiveness of amantadine (midantan) in the treatment of the parkinsonian syndrome Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 76(2): 174-178
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Andrews, C.J. 1972: Amantadine and L-dopa Australian and New Zealand Journal of Medicine 2(3): 292-293
Horiguchi, J.; Inami, Y.; Miyoshi, N.; Kakimoto, Y. 1985: Restless legs syndrome in four parkinsonian patients treated with amantadine Rinsho Shinkeigaku 25(2): 153-156
Danielczyk, W.; Korten, J.J. 1971: Action of amantadine HCl alone and in combination with L-dopa on parkinsonism Medizinische Monatsschrift 25(10): 472-479
Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16
Ferraris, M. 1971: Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa Minerva Medica 62(82): 3971-3973
Fischer, P.A. 1974: Therapy of Parkinsonian syndrome using L-dopa. Current state and problems Der Nervenarzt 45(12): 617-627
Peppe, A.; Dambrosia, J.M.; Chase, T.N. 1993: Risk factors for motor response complications in L-dopa-treated parkinsonian patients Advances in Neurology 60: 698-702
Gersten, J.W.; Marshall, C.; Dillon, T.; Schneck, S.A.; Orr, W.; Nelson, C. 1972: External work of walking and functional capacity in Parkinsonian patients treated with L-dopa Archives of Physical Medicine and Rehabilitation 53(12): 547-553
Ransmayr, G.; Künig, G.; Neubauer, M.; Wagner, M.; Bösch, S.; Kreczy-Kleedorfer, B. 1993: Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies? Advances in Neurology 60: 685-689